Multiple myeloma (MM) is the second most common blood cancer. Treatments for MM
include corticosteroids, alkylating agents, anthracyclines, proteasome inhibitors …

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

Abstract The International Myeloma Working Group consensus updates the definition for
high-risk (HR) multiple myeloma based on cytogenetics Several cytogenetic abnormalities …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than
20,000 people annually in the United States. There has been a veritable revolution in this …

Myeloma is a malignant proliferation of monoclonal plasma cells. Although morphologically
similar, several subtypes of the disease have been identified at the genetic and molecular …

PURPOSE The wide heterogeneity in multiple myeloma (MM) outcome is driven mainly by
cytogenetic abnormalities. The current definition of high-risk profile is restrictive and …

To better define the molecular basis of multiple myeloma (MM), we performed unsupervised
hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 …

Cytogenetic abnormalities are found in most multiple myeloma (MM) patients. Although their
prognostic value has been well studied, there are limited data on the association of primary …

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These
neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone …